- Home
- RNG vs KNSA Comparison
RNG vs KNSA Comparison
Compare RNG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | KNSA |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNG | KNSA |
|---|---|---|
| Price | $36.96 | $47.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $33.58 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 1.4M | 534.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | 176.19 | ★ 225.00 |
| EPS | 0.48 | ★ 0.75 |
| Revenue | ★ $2,515,142,000.00 | $677,564,000.00 |
| Revenue This Year | $5.56 | $38.01 |
| Revenue Next Year | $4.56 | $17.42 |
| P/E Ratio | $69.80 | ★ $62.71 |
| Revenue Growth | 4.78 | ★ 60.09 |
| 52 Week Low | $21.91 | $19.62 |
| 52 Week High | $42.42 | $50.03 |
Technical Indicators
Market Signals| Indicator | RNG | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 52.06 |
| Support Level | $25.58 | $39.96 |
| Resistance Level | $39.74 | $48.61 |
| Average True Range (ATR) | 2.15 | 1.85 |
| MACD | -0.39 | -0.07 |
| Stochastic Oscillator | 56.57 | 48.67 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.